1887

Access Microbiology open research platform logo

Volume 3, Issue 11

Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against ATCC17978 or AB030 Open Access

Abstract

With the current arsenal of antibiotics increasingly becoming ineffective against bacteria, there is an increasing interest in the possibility of using previously approved non-antibiotic drugs as antimicrobials. Statins have recently been investigated for their antimicrobial activity and their ability to potentially synergize with current treatment options. Atorvastatin had been shown previously to be the most promising candidate for effectivity against ATCC17978. In this study, we tested atorvastatin for its activity against an extensively drug-resistant (XDR) strain AB030. However, our data show that atorvastatin has no effect AB030. Intriguingly, atorvastatin was also ineffective against our laboratory’s ATCC17978. This lack of atorvastatin activity against ATCC17978 cannot be attributed to RND efflux pumps as a strain deficient in the three most clinically relevant RND efflux systems in showed no change in susceptibility compared to its parent strain ATCC17978. Further, atorvastatin failed to potentiate the activity of tobramycin and ciprofloxacin. While it is not clear to us why atorvastatin is not active against ATCC17978 used in our study, our study shows that evaluation of compounds for their antibacterial activity should involve multiple strains to account for strain-to-strain variation.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): drug development , drug repurposing , Gram-negative and multidrug resistance
Funding
This study was supported by the:
  • Natural Sciences and Engineering Research Council of Canada (Award RGPIN-2021-02902)
    • Principle Award Recipient: Ayushkumar
© 2021 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000288
2021-11-30
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/acmi/3/11/acmi000288.html?itemId=/content/journal/acmi/10.1099/acmi.0.000288&mimeType=html&fmt=ahah

References

  1. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B et al. Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges. Clin Microbiol Rev 2017; 30:409–447 [View Article] [PubMed]
     [Google Scholar]
  2. McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev 2013; 37:130–155 [View Article] [PubMed]
     [Google Scholar]
  3. World Health Organization WHO publishes list of bacteria for which new antibiotics are urgently needed; 2017 http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/
  4. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015; 36:85–98 [View Article] [PubMed]
     [Google Scholar]
  5. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46:1254–1263 [View Article] [PubMed]
     [Google Scholar]
  6. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2007; 61:362–364 [View Article]
     [Google Scholar]
  7. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89–118 [View Article]
     [Google Scholar]
  8. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: Population based prospective cohort study. BMJ 2006; 333:999 [View Article] [PubMed]
     [Google Scholar]
  9. Hennessy E, Adams C, Reen FJ, O’Gara F. Is there potential for repurposing statins as novel antimicrobials?. Antimicrob Agents Chemother 2016; 60:5111–5121 [View Article] [PubMed]
     [Google Scholar]
  10. Haeri MR, White K, Qharebeglou M, Ansar MM. Cholesterol suppresses antimicrobial effect of statins. Iran J Basic Med Sci 2015; 18:1253–1256 [PubMed]
     [Google Scholar]
  11. Masadeh M, Mhaidat N, Alzoubi K, Al-Azzam S, Alnasser Z. Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin. Ann Clin Microbiol Antimicrob 2012; 11:1–1313 [View Article] [PubMed]
     [Google Scholar]
  12. Choi K-H, Schweizer HP. An improved method for rapid generation of unmarked Pseudomonas aeruginosa deletion mutants. BMC Microbiol 2005; 5:30 [View Article] [PubMed]
     [Google Scholar]
  13. Hamad MA, Zajdowicz SL, Holmes RK, Voskuil MI. An allelic exchange system for compliant genetic manipulation of the select agents Burkholderia pseudomallei and Burkholderia mallei. Gene 2009; 430:123–131 [View Article] [PubMed]
     [Google Scholar]
  14. Yildirim S, Thompson MG, Jacobs AC, Zurawski DV, Kirkup BC. Evaluation of parameters for high efficiency transformation of Acinetobacter baumannii. Sci Rep 2016; 6:22110 [View Article]
     [Google Scholar]
  15. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing. In CLSI Supplement M100, 31st. edn Clinical and Laboratory Standards Institute; 2021
     [Google Scholar]
  16. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45:105–116 [View Article] [PubMed]
     [Google Scholar]
  17. Kornelsen V, Kumar A. Update on multidrug resistance efflux pumps in Acinetobacter spp. Antimicrob Agents Chemother 2021; 65:e0051421 [View Article] [PubMed]
     [Google Scholar]
  18. Farmer AR, Murray CK, Mende K, Akers KS, Zera WC et al. Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for Gram-negative rods. J Basic Microbiol 2013; 53:336–339 [View Article] [PubMed]
     [Google Scholar]
  19. Mima T, Schweizer HP. The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. Antimicrob Agents Chemother 2010; 54:3113–3120 AAC.01803-09 [View Article]
     [Google Scholar]
  20. Maseda H, Saito K, Nakajima A, Nakae T. Variation of the mexT gene, a regulator of the MexEF-OprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. FEMS Microbiol Lett 2000; 192:107–112 [View Article] [PubMed]
     [Google Scholar]
  21. Fernando D, Zhanel G, Kumar A. Antibiotic resistance and expression of resistance-nodulation-division pump- and outer membrane porin-encoding genes in Acinetobacter species isolated from Canadian hospitals. Can J Infect Dis Med Microbiol 2013; 24:17–21 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000288
Loading
Atorvastatin does not display an antimicrobial activity on its own nor potentiates the activity of other antibiotics against Acinetobacter baumannii ATCC17978 or A. baumannii AB030
Access Microbiology 3, 000288 (2021); https://doi.org/10.1099/acmi.0.000288
/content/journal/acmi/10.1099/acmi.0.000288
/content/journal/acmi/10.1099/acmi.0.000288
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error